Groundbreaking experimentation in 2006 led to the introduction of induced pluripotent stem cells (iPSCs). These are adult cells which are isolated and then transformed into embryonic-like stem cells through the manipulation of gene expression, as well as other methods. Research and experimentation using mouse cells at Kyoto University in Japan was the first instance in which there was successful generation of induced pluripotent stem cells. Then in 2007, a series of follow-up experiments done at Kyoto University successfully transformed human adult cells into iPSCs.
While there is widespread excitement regarding what these artificially re-manufactured cells can contribute to medical advances, there have also been issues, some of which have been prohibitive. By 2010, there were a number of private companies ready to capitalize on the breakthrough technology that iPSCs represent. One such company, Advanced Cell Technology in Worcester, Massachusetts, discovered problematic issues as they conducted experiments prior to applying for U.S. Food and Drug Administration approval for using induced pluripotent stem cells in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced.
Stemming from both iPSC research advances and set-backs, a large and thriving products market has grown into existence. The number of iPSC research products sold worldwide has been growing at an annual rate of 14.7% over the past five years. In addition, 22.1% of all stem cell researchers now self-report as having used induced pluripotent stem cells within a research project. It is clear that iPSCs are a vital research trend within the scientific community.
Presenting new 2014 data, the "Complete 2013-14 Induced Pluripotent Stem Cell Industry Report" addresses these trends by strategically positioning companies to expand, profit, and outmaneuver the competition.
A distinctive feature of the report is the findings discovered as a result of surveying 274 researchers (131 U.S. / 143 International) that identify as having induced pluripotent stem cells as their core focus. This 2014 survey reveals iPSC researcher needs, technical preferences, key factors influencing buying decisions, and much more. They can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.
To benefit from this lucrative product market, you need to anticipate and serve the needs of your clients, or your competitors will.
Key Findings Include: